drugset / Trial / NCT01875393

Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

NCT01875393 ↗

Phase 3 Completed 81 enrolled Steba Biotech S.A.
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to confirm the Efficacy,the Safety and the Quality of Life after TOOKAD® Soluble VTP in localized prostate cancer patients.

Timeline

Start
2013-05
Primary completion
2014-12
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject TOOKAD Soluble Unknown 4 mg/kg Intravenous

Indications